298 related articles for article (PubMed ID: 29649630)
1. Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma.
Fan Z; Xia H; Xu H; Ma J; Zhou S; Hou W; Tang Q; Gong Q; Nie Y; Bi F
Biomed Pharmacother; 2018 Jul; 103():147-156. PubMed ID: 29649630
[TBL] [Abstract][Full Text] [Related]
2. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
3. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
Guo C; Wang X; Liang L
Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
[TBL] [Abstract][Full Text] [Related]
4. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
5. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
[TBL] [Abstract][Full Text] [Related]
6. Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Liu C; Peng X; Li Y; Liu S; Hou R; Zhang Y; Zuo S; Liu Z; Luo R; Li L; Fang W
Biomed Pharmacother; 2020 Mar; 123():109780. PubMed ID: 31901550
[TBL] [Abstract][Full Text] [Related]
7. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
Dang H; Steinway SN; Ding W; Rountree CB
BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
[TBL] [Abstract][Full Text] [Related]
8. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line.
Asai R; Tsuchiya H; Amisaki M; Makimoto K; Takenaga A; Sakabe T; Hoi S; Koyama S; Shiota G
Cancer Med; 2019 Feb; 8(2):773-782. PubMed ID: 30636370
[TBL] [Abstract][Full Text] [Related]
9. Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression.
Yu S; Cai X; Wu C; Wu L; Wang Y; Liu Y; Yu Z; Qin S; Ma F; Thiery JP; Chen L
Oncotarget; 2015 Feb; 6(5):2951-65. PubMed ID: 25605020
[TBL] [Abstract][Full Text] [Related]
10. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
11. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice.
Cai WY; Lin LY; Hao H; Zhang SM; Ma F; Hong XX; Zhang H; Liu QF; Ye GD; Sun GB; Liu YJ; Li SN; Xie YY; Cai JC; Li BA
Hepatology; 2017 Apr; 65(4):1206-1221. PubMed ID: 27809333
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.
Endo K; Terada T
J Hepatol; 2000 Jan; 32(1):78-84. PubMed ID: 10673070
[TBL] [Abstract][Full Text] [Related]
13. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
14. The novel interplay between CD44 standard isoform and the caspase-1/IL1B pathway to induce hepatocellular carcinoma progression.
Li J; Zhang Y; Ruan R; He W; Qian Y
Cell Death Dis; 2020 Nov; 11(11):961. PubMed ID: 33168816
[TBL] [Abstract][Full Text] [Related]
15. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma.
Huo X; Zhang Q; Liu AM; Tang C; Gong Y; Bian J; Luk JM; Xu Z; Chen J
Oncol Rep; 2013 Feb; 29(2):840-6. PubMed ID: 23232767
[TBL] [Abstract][Full Text] [Related]
17. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
18. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma.
Wang J; Tang X; Weng W; Qiao Y; Lin J; Liu W; Liu R; Ma L; Yu W; Yu Y; Pan Q; Sun F
Oncogene; 2015 Nov; 34(47):5781-95. PubMed ID: 25728681
[TBL] [Abstract][Full Text] [Related]
19. YAP1-activated ZNF131 promotes hepatocellular carcinoma cell proliferation through transcriptional regulation of PAIP1.
Yin G; Jia S; Zhang Y; Xian Y; Guo Y; Liu Q
Arch Biochem Biophys; 2024 Apr; 754():109921. PubMed ID: 38341068
[TBL] [Abstract][Full Text] [Related]
20. CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma.
Okabe H; Ishimoto T; Mima K; Nakagawa S; Hayashi H; Kuroki H; Imai K; Nitta H; Saito S; Hashimoto D; Chikamoto A; Ishiko T; Watanabe M; Nagano O; Beppu T; Saya H; Baba H
Br J Cancer; 2014 Feb; 110(4):958-66. PubMed ID: 24300972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
